MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company’s flagship product was approved by the US Food and Drug Administration in December 2020. MacroGenics generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability…
ADC Therapeutics. Confronting cancer with the full potential of our science. ADC Therapeutics is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs). ADC Therapeutics is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. …
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. MI Exome™…
About Oncopeptides Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. In 2000, the Company was formed by some of Sweden’s most leading scientists with ties preeminent oncology research institutions. Oncopeptides’ headquarters is in Stockholm, Sweden with a U.S. headquarters in Boston, Massachusetts. In addition to Boston, Oncopeptides…
Gilead, is a leader in next generation antibody-drug conjugate (ADC) technology, committed to helping people with hard-to-treat cancers. The impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next. Their goal is to discover, identify and evaluate investigational compounds that show potential to advance the treatment of…
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the…
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies…
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera’s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types…
Founded in March 2015, EUSA Pharma is a profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. EUSA Pharma is a rapidly growing while staying focused in oncology and rare disease. Our mission at EUSA is that we are passionate and committed…
Coherus is led by a team of biotech industry pioneers focused on disrupting the status-quo and driving tangible change in healthcare. Many of our leaders were directly involved in developing, manufacturing, and commercializing blockbuster biologics that elevated biologics from niche to mainstream medicine. Today, the team is unlocking the true potential of this category and…
At EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany, in the US and Canada, our scientific approach in oncology focuses on oncogenic pathways, immuno-oncology, and DNA damage response. To deliver breakthrough cancer therapies, we complement our internal expertise and development programs with scientific collaborations to improve trial designs, accelerate treatment development, and…
Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.
For more information about Pharmacyclics LLC, an AbbVie Company, please visit pharmacyclics.com.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products…
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical need. With our leading-edge processes in manufacturing, strong pipeline of treatments and reliable supply, we strive to improve patient access to more affordable,…
Eisai’s Commitment to Oncology Eisai’s hhc (human health care) mission is to give first thoughts to patients and their families by developing drugs for diseases with significant unmet medical need. Nowhere is this more compelling than in oncology, one of Eisai’s long-standing therapeutic areas of focus since 1987. Eisai continues to grow its commitment to…
Taiho Oncology, Inc., a division of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has built a world class clinical development organization that works urgently to develop innovative cancer treatments. Taiho has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state of the…
Company Overview Patient Assistance Programs Overview People are at the heart of what drives Teva Oncology. As a top 10 oncology company in the US, we strive to improve the lives of people affected by cancer. Our focus is to provide solutions in hematologic malignancies, solid tumors and supportive care. At Teva Oncology, our vision…
For more than 30 years, Janssen Biotech, Inc. has delivered on the promise of new treatments and ways to improve the health of individuals with serious disease. Built upon a rich legacy of innovative firsts, Janssen Biotech, Inc. pursues innovative solutions in the therapeutic areas of immunology, oncology, urology and nephrology. With the same unwavering…
There’s a time when everything changes. That life-altering moment when someone hears, “You have cancer.” That moment is what motivates everyone at Lilly Oncology. Patient TruAssist Program PatientOne Assistance Program
© 2021 FLASCO | Premium Website Design by The HDG
